Literature DB >> 21451445

Approaches to avoid immune responses induced by repeated subcutaneous injections of allogeneic umbilical cord tissue-derived cells.

Bram V Lutton1, Patricia S Cho, Erica L Hirsh, Kelly K Ferguson, Alexander G S Teague, John S Hanekamp, Nina Chi, Stephanie N Goldman, Darin J Messina, Stuart Houser, Beow Y Yeap, Sicco H Popma, David H Sachs, Christene A Huang.   

Abstract

BACKGROUND: Cellular treatments for repairing diseased tissues represent a promising clinical strategy. Umbilical cord tissue-derived cells (UTC) are a unique source of cells with a low immunogenic profile and potential for tissue repair. By using UTC from miniature swine, we previously demonstrated that despite their low immunogenic phenotype, UTC could induce an immune response under certain inflammatory conditions and after multiple subcutaneous (SC) injections. Given that repeat dosing of cells may be necessary to achieve a lasting therapeutic benefit, in this study, we examined approaches to avoid an immune response to multiple SC injections of UTC.
METHODS: By using in vitro and in vivo measures of sensitization to SC cellular injections, we assessed the effects of varying the location of administration site, prolongation of timing between injections, and use of immunosuppressive treatments on repeated cellular injections in Massachusetts General Hospital major histocompatibility complex-defined miniature swine.
RESULTS: Although under normal conditions, a single SC injection of major histocompatibility complex-mismatched UTC did not induce a detectable immune response, multiple SC injections of UTC demonstrated rapid humoral and cell-mediated immune responses. Avoidance of an immune response to repeat SC injection was achieved by concurrent immunosuppression with each dose of UTC.
CONCLUSIONS: UTC and other similar cell types believed to be nonimmunogenic have the potential to induce immune responses under certain conditions. These studies provide important considerations and guidelines for preclinical studies investigating allogeneic cellular therapies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21451445      PMCID: PMC3740357          DOI: 10.1097/TP.0b013e3181c6ff73

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  18 in total

1.  In utero induction of transplantation tolerance.

Authors:  D W Mathes; K Yamada; M A Randolph; R Utsugi; M G Solari; G S Gazelle; A Wu; D H Sachs; W P Lee
Journal:  Transplant Proc       Date:  2001 Feb-Mar       Impact factor: 1.066

2.  Increased T-cell activation in decidua parietalis compared to decidua basalis in uncomplicated human term pregnancy.

Authors:  A Sindram-Trujillo; S Scherjon; H Kanhai; D Roelen; F Claas
Journal:  Am J Reprod Immunol       Date:  2003-05       Impact factor: 3.886

3.  Transplantation in miniature swine. VI. Factors influencing survival of renal allografts.

Authors:  R L Kirkman; R B Colvin; M W Flye; G S Leight; S A Rosenberg; G M Williams; D H Sachs
Journal:  Transplantation       Date:  1979-07       Impact factor: 4.939

4.  Role of the thymus in transplantation tolerance in miniature swine: II. Effect of steroids and age on the induction of tolerance to class I mismatched renal allografts.

Authors:  K Yamada; P R Gianello; F L Ierino; J Fishbein; T Lorf; A Shimizu; R B Colvin; D H Sachs
Journal:  Transplantation       Date:  1999-02-15       Impact factor: 4.939

Review 5.  Effect of major histocompatibility complex matching on the development of tolerance to primarily vascularized renal allografts: a study in miniature swine.

Authors:  P R Gianello; D H Sachs
Journal:  Hum Immunol       Date:  1996-09-15       Impact factor: 2.850

6.  Development of tolerance to class II-mismatched renal transplants after a short course of cyclosporine therapy in miniature swine.

Authors:  J M Fishbein; B R Rosengard; P Gianello; V Nickeleit; P C Guzzetta; C V Smith; K Nakajima; D Vitiello; G M Hill; D H Sachs
Journal:  Transplantation       Date:  1994-05-15       Impact factor: 4.939

7.  Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH).

Authors:  O N Koç; J Day; M Nieder; S L Gerson; H M Lazarus; W Krivit
Journal:  Bone Marrow Transplant       Date:  2002-08       Impact factor: 5.483

8.  Transplantation of pig stem cells into rat brain: proliferation during the first 8 weeks.

Authors:  S Medicetty; A R Bledsoe; C B Fahrenholtz; D Troyer; M L Weiss
Journal:  Exp Neurol       Date:  2004-11       Impact factor: 5.330

9.  Transplantation of porcine umbilical cord matrix cells into the rat brain.

Authors:  M L Weiss; K E Mitchell; J E Hix; S Medicetty; S Z El-Zarkouny; D Grieger; D L Troyer
Journal:  Exp Neurol       Date:  2003-08       Impact factor: 5.330

10.  Effect of class II antigen matching on renal allograft survival in miniature swine.

Authors:  M D Pescovitz; J R Thistlethwaite; H Auchincloss; S T Ildstad; T G Sharp; R Terrill; D H Sachs
Journal:  J Exp Med       Date:  1984-11-01       Impact factor: 14.307

View more
  4 in total

1.  Decellularized Tooth Bud Scaffolds for Tooth Regeneration.

Authors:  W Zhang; B Vazquez; D Oreadi; P C Yelick
Journal:  J Dent Res       Date:  2017-01-24       Impact factor: 6.116

Review 2.  Mesenchymal Stem Cells, Bioactive Factors, and Scaffolds in Bone Repair: From Research Perspectives to Clinical Practice.

Authors:  Sandra Stamnitz; Aleksandra Klimczak
Journal:  Cells       Date:  2021-07-29       Impact factor: 6.600

3.  Macroscopic, Histologic, and Immunomodulatory Response of Limb Wounds Following Intravenous Allogeneic Cord Blood-Derived Multipotent Mesenchymal Stromal Cell Therapy in Horses.

Authors:  Suzanne J K Mund; Daniel J MacPhee; John Campbell; Ali Honaramooz; Bruce Wobeser; Spencer M Barber
Journal:  Cells       Date:  2021-11-01       Impact factor: 6.600

4.  Epiretinal membrane in a subject after transvitreal delivery of palucorcel (CNTO 2476).

Authors:  Rand Spencer; Steven Fisher; Geoffrey P Lewis; Terri Malone
Journal:  Clin Ophthalmol       Date:  2017-10-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.